GSK (NYSE:GSK) Stock Rating Reaffirmed as “Buy” by Berenberg Bank

GSK (NYSE:GSK)‘s stock had its “buy” rating reaffirmed by investment analysts at Berenberg Bank in a research report issued to clients and investors on Tuesday.

Several other research analysts have also commented on GSK. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of GSK in a research report on Thursday, July 30th. Morgan Stanley restated an “underweight” rating on shares of GSK in a research note on Tuesday, August 25th. Royal Bank Of Canada started coverage on shares of GSK in a report on Tuesday, September 8th. They issued a “sector perform” rating for the company. Weiss Ratings lowered shares of GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Finally, Wolfe Research started coverage on shares of GSK in a report on Friday. They set an “outperform” rating and a $70.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $55.33.

GSK Stock Down 0.1%

Shares of GSK traded down $0.04 during midday trading on Tuesday, hitting $46.49. The company had a trading volume of 8,542,712 shares, compared to its average volume of 4,225,426. The stock has a market cap of $94.05 billion, a price-to-earnings ratio of 14.54, a PEG ratio of 2.09 and a beta of 0.33. The company’s 50 day moving average price is $50.02 and its 200 day moving average price is $51.83. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81. GSK has a 52 week low of $42.85 and a 52 week high of $61.69.

GSK (NYSE:GSK) last issued its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.27 by $0.09. The business had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.47 earnings per share. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, equities research analysts predict that GSK will post 4.78 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in GSK. Security National Bank of SO Dak bought a new position in shares of GSK in the second quarter worth $38,000. Trust Co. of Vermont bought a new position in GSK in the 2nd quarter valued at about $54,000. Philadelphia Investment Partners LLC acquired a new position in GSK during the 2nd quarter valued at about $70,000. Ancora Advisors LLC acquired a new position in GSK during the 2nd quarter valued at about $71,000. Finally, Bogart Wealth LLC raised its position in shares of GSK by 15.3% during the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after buying an additional 200 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “outperform” rating and a $70 price target, implying substantial upside from current levels. Berenberg Bank also reaffirmed its “buy” rating, reinforcing favorable sell-side sentiment.
• Positive Sentiment: GSK plans to invest more than $800 million in a new Upper Merion, Pennsylvania biopharmaceutical facility, which is expected to create approximately 300 jobs. The investment could expand manufacturing and research capacity and strengthen GSK’s U.S. operating footprint. GSK commits $800M to build new Upper Merion facility as pharma investment surges
• Positive Sentiment: AI drug-design company Chai Discovery announced a collaboration with GSK following a successful wet-lab evaluation. The partnership could support faster discovery and development of new medicines, although its financial impact is not yet disclosed. Chai Discovery Announces Collaboration with GSK Following Successful Wet-Lab Evaluation
• Positive Sentiment: GSK is deepening its pipeline through partnerships with Wave Life Sciences on a liver-disease GalNAc-siRNA candidate and AN2 Therapeutics on tuberculosis research, supported by Gates Foundation funding. These deals broaden potential future growth but remain dependent on clinical and regulatory progress. GSK Deepens Its Drug Pipeline Through Two Research Partnerships
• Neutral Sentiment: GSK launched a shingles-awareness campaign with Viola Davis aimed at adults aged 50 and older. The campaign may support vaccine demand and brand awareness, but it is primarily educational and has no quantified near-term revenue impact. Viola Davis partners with GSK to educate adults 50 and older about their shingles risk
• Neutral Sentiment: Investors are looking ahead to GSK’s upcoming quarterly results after the trading window closed. The report remains the next major potential catalyst for valuation and guidance.

About GSK

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.